# InformAI

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/informai

- Industry: Healthcare IT
- Headquarters: Houston, US
- Website: www.informai.com
- Total disclosed funding: $1.8M
- Latest round: Seed (Jun 26, 2020)
- Investors on record: 3

## About

InformAI, LLC specializes in AI-driven enterprise software solutions aimed at enhancing healthcare delivery in radiology, radiation oncology, and high-acuity informatics.Founded in 2017 and headquartered in Houston, US, InformAI, LLC provides AI solutions for healthcare. The company's CEO, Jim Havelka, has a background in leading technology initiatives. InformAI has completed 2 deals, with the most recent funding round being a Seed round of USD 1.8 mn led by DEFTA Partners on June 26, 2020, with participation from Social Starts and Joyance Partners.InformAI's core offerings encompass a suite of AI-driven enterprise software solutions designed to enhance healthcare delivery across critical medical fields, including radiology, radiation oncology, and high-acuity informatics. The flagship product, RadOncAI, optimizes radiation therapy by generating individualized treatment plans that effectively target tumors while minimizing damage to surrounding healthy tissues. Additionally, the company develops TransplantAI, a sophisticated donor-recipient informatics platform that facilitates precise, AI-powered transplant decision-making at the point of care. SinusAI further augments diagnostic capabilities in CT imaging through AI-enabled precision and efficiency. InformAI's solutions cater to a diverse client base, including elite medical institutions within the United States and international markets, directly impacting healthcare providers and clinicians who strive to improve patient outcomes.InformAI generates revenue through partnerships and direct sales of its AI-driven software solutions to healthcare organizations and institutions. The company adopts a B2B transaction structure, typically engaging in contractual agreements that may include subscription models for ongoing software access, as well as one-time licensing fees for specific products. While precise pricing details are proprietary, such transactions often reflect the value provided by flagship products like RadOncAI, TransplantAI, and SinusAI, which are essential in modernizing clinical practices and enhancing patient care. InformAI's revenue streams are further supported by collaborations with healthcare providers, allowing for seamless integration and deployment of their cutting-edge solutions within clinical settings.InformAI plans to leverage the recent Seed funding of USD 1.8 mn raised in June 2020 to enhance its product offerings and enter new markets. The company is focused on expanding its AI solutions, possibly introducing new enhancements to RadOncAI and TransplantAI in the coming months. Additionally, InformAI is targeting expansion into international markets within Europe and Asia by the end of 2023, aiming to establish partnerships with healthcare institutions in these regions, thereby broadening its impact on global healthcare delivery.

## Funding rounds

- Seed, Jun 26, 2020, $1.8M — DEFTA Partners, Social Starts, Joyance Partners
- Seed, Jan 28, 2020 — Joyance Partners

## Investors

- Joyance Partners (https://capitalatlas.ai/funds/joyance-partners) — Seed
- DEFTA Partners (https://capitalatlas.ai/funds/defta-partners) — Seed
- Social Starts (https://capitalatlas.ai/funds/social-starts) — Seed